Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTEX6LM)

• DTT Name: GABA(A) receptor gamma-3 (GABRG3) DTT Info
• Gene Name: GABRG3

Molecule-Related Drug & Molecule List

14 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[1]
Bentazepam	DMRVBWU	Anxiety disorder	6B00-6B0Z	Approved	[2]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[3]
Etomidate	DMZI3WO	Anaesthesia	9A78.6	Approved	[3]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[4]
Ganaxolone	DMXJMKF	Epileptic seizures	8A61-8A6Z	Approved	[1]
Mebutamate	DM0KYI4	Anxiety disorder	6B00-6B0Z	Approved	[3]
Metharbital	DM5A38V	Epilepsy	8A60-8A68	Approved	[3]
Remimazolam	DMLVSYX	Procedural sedation	JB0C.3	Approved	[5]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[6]
Talbutal	DM214Q8	Irritability	MB24	Approved	[3]
Thiamylal	DMHDF7B	Anaesthesia	9A78.6	Approved	[3]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[4]
Zuranolone	DMGR98T	Postpartum depression	6E20.0	Approved	[1]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arbaclofen placarbil	DMO628K	Fragile X syndrome	LD55	Phase 3	[1]
Clomethiazole	DMSPN58	Stroke	8B20	Phase 3	[7]
Pagoclone	DMHWY2G	Anxiety disorder	6B00-6B0Z	Phase 2/3	[8]
Etazolate	DMOCID7	Neurodegenerative disorder	8A20-8A23	Phase 2	[9]
EVT-201	DMQGBM1	Insomnia	7A00-7A0Z	Phase 2	[4]
SARIPIDEM	DM5R89X	Anxiety disorder	6B00-6B0Z	Phase 2	[10]
T-2007	DMF9Z2T	Epilepsy	8A60-8A68	Phase 2	[4]
AZD-3043	DMXFYN0	Anaesthesia	9A78.6	Phase 1	[11]
NSD-788	DM5QHID	Anxiety disorder	6B00-6B0Z	Phase 1	[4]
Org-25435	DMBG534	Epilepsy	8A60-8A68	Phase 1	[12]

21 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Suriclone	DMC14HL	Anxiety disorder	6B00-6B0Z	Discontinued in Preregistration	[13]
Ocinaplon	DMQN3JX	Generalized anxiety disorder	6B00	Discontinued in Phase 3	[14]
Pazinaclone	DM1FST8	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[15]
Y-23684	DM3EZ68	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[16]
LORECLEZOLE	DMCZI62	Epileptic seizures	8A61-8A6Z	Discontinued in Phase 2	[17]
NGD 91-3	DMDAUCR	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 2	[18]
RESEQUINIL	DM3EAYN	Epilepsy	8A60-8A68	Discontinued in Phase 2	[19]
RO-48-6791	DMH912O	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 2	[20]
SL-65.1498	DMS8AHE	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 2	[21]
Suritozole	DMDZ7AY	Major depressive disorder	6A70.3	Discontinued in Phase 2	[22]
CCD-3693	DMMEC1W	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[23]
CTP-354	DMXY43L	Pain	MG30-MG3Z	Discontinued in Phase 1	[24]
Org-21465	DMMYI9U	Anaesthesia	9A78.6	Discontinued in Phase 1	[25]
RO-48-8684	DMOX8AD	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[26]
Co-152791	DMU5TZD	Epilepsy	8A60-8A68	Terminated	[28]
Girisopam	DMSVMF2	Anxiety disorder	6B00-6B0Z	Terminated	[29]
NSD-721	DMF2XMA	Anxiety disorder	6B00-6B0Z	Terminated	[4]
Ro-19-8022	DMFRCM2	Anxiety disorder	6B00-6B0Z	Terminated	[30]
RU-33965	DMSWFMQ	Alzheimer disease	8A20	Terminated	[31]
ZK-91296	DMJYIVA	Alzheimer disease	8A20	Terminated	[32]
ZK-93426	DMMDQ5T	Alzheimer disease	8A20	Terminated	[33]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RWJ-51204	DMMVS07	Anxiety disorder	6B00-6B0Z	Preclinical	[27]

25 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AA-29504	DMI59T7	Major depressive disorder	6A70.3	Investigative	[4]
alpha3IA	DM257WX	Discovery agent	N.A.	Investigative	[4]
alpha5IA	DMTU5QR	Discovery agent	N.A.	Investigative	[4]
C-21191	DMCAO3V	Anxiety disorder	6B00-6B0Z	Investigative	[4]
CP-409092	DMROYD7	Discovery agent	N.A.	Investigative	[34]
DMCM	DMK3WY4	Discovery agent	N.A.	Investigative	[4]
DOV-51892	DMQIK9S	Panic disorder	6B01	Investigative	[4]
GIDAZEPAM	DMASR6T	Anxiety disorder	6B00-6B0Z	Investigative	[35]
HZ-166	DMLU6VM	Neuropathic pain	8E43.0	Investigative	[4]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[4]
JM-1232(-)	DMWMRO2	Anaesthesia	9A78.6	Investigative	[4]
NGD 96-3	DMWD7I3	Insomnia	7A00-7A0Z	Investigative	[4]
piperidine-4-sulphonic acid	DMMIZWE	Discovery agent	N.A.	Investigative	[4]
PNU 101017	DMKBCS2	Discovery agent	N.A.	Investigative	[36]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[37]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[4]
tetrahydrodeoxycorticosterone	DMF8M0W	Discovery agent	N.A.	Investigative	[4]
TP003	DMRHDGN	Discovery agent	N.A.	Investigative	[4]
UC-1011	DMCRFT5	Alzheimer disease	8A20	Investigative	[4]
UC-2024	DMJVT4K	Premenstrual syndrome	GA34.40	Investigative	[4]
UC-2029	DMGSOZ7	Premenstrual syndrome	GA34.40	Investigative	[4]
[18F]fluoroethylflumazenil	DMPWART	Discovery agent	N.A.	Investigative	[4]
[35S]TBPS	DMSD51L	Discovery agent	N.A.	Investigative	[4]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[4]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [6] Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
• [7] Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors. Eur J Pharmacol. 2002 Oct 11;452(3):255-62.
• [8] Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73.
• [9] Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008 Jul;106(1):392-404.
• [10] Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol. 1995 Mar;6(2):116-126.
• [11] AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012 Jun;116(6):1267-77.
• [12] First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial. BMC Anesthesiol. 2010 Jun 29;10:10.
• [13] The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):294-300.
• [14] Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
• [15] The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs. 2005 May;14(5):601-18.
• [16] The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br J Pharmacol. 1994 Apr;111(4):1170-8.
• [17] Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.
• [18] Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord. 2003 Aug;2(4):213-32.
• [19] WO patent application no. 2010,0024,51, Naphthyridin derivatives.
• [20] Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997 Nov;44(5):477-86.
• [21] WO patent application no. 2005,0749,31, Pharmaceutical combinations comprising (s) -pantoprazole.
• [22] Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. J Neurosurg. 1995 Nov;83(5):878-83.
• [23] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [24] Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
• [25] Computer-controlled infusion of ORG 21465, a water soluble steroid i.v. anaesthetic agent, into human volunteers. Br J Anaesth. 1997 Oct;79(4):433-9.
• [26] Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997 Nov;44(5):487-93.
• [27] 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90.
• [28] Substituted 3beta-phenylethynyl derivatives of 3alpha-hydroxy-5alpha-pregnan-20-one: remarkably potent neuroactive steroid modulators of gamma-aminobutyric acidA receptors. J Pharmacol Exp Ther. 1998Oct;287(1):198-207.
• [29] [(3)H]-girisopam, a novel selective benzodiazepine for the 2, 3-benzodiazepine binding site. Brain Res Brain Res Protoc. 1999 Jul;4(2):230-5.
• [30] Partial agonist of benzodiazepine receptors Ro 19-8022 elicits withdrawal symptoms after short-term administration in immature rats. Physiol Res. 2012;61(3):319-23.
• [31] Discriminative stimulus properties of RU 33965, a benzodiazepine receptor weak partial inverse agonist. Pharmacol Biochem Behav. 1992 Oct;43(2):583-8.
• [32] Enhancement of gamma-aminobutyric acid binding by the anxiolytic beta-carbolines ZK 93423 and ZK 91296. J Neurochem. 1987 May;48(5):1355-8.
• [33] Actions of the beta-carboline ZK 93426 in an animal test of anxiety and the holeboard: interactions with Ro 15-1788. J Neural Transm. 1986;65(2):103-14.
• [34] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [35] Discriminative effects of phenazepam and gidazepam in rats: comparison with other GABA-related drugs. Pharmacol Biochem Behav. 1999 Oct;64(2):397-401.
• [36] Neuroprotective effects of the GABA(A) receptor partial agonist U-101017 in 3-acetylpyridine-treated rats. Neurosci Lett. 1997 May 30;228(1):45-9.
• [37] Molecular structure and stereoelectronic properties of sarmazenil--a weak inverse agonist at the omega modulatory sites (benzodiazepine receptors):... Bioorg Med Chem. 1998 Oct;6(10):1745-57.